From JPMA Aiming for a country where innovation is dynamic
On January 1, 2024, the Noto Peninsula Earthquake of 2024 occurred. We would like to express our deepest condolences to those who lost their lives and our deepest sympathies to all those who were affected by the earthquake. In response to requests from local governments, the Ministry of Health, Labor and Welfare, and medical organizations, the Pharmaceutical Manufacturers Association of Japan (PMAJ) is committed to ensuring a stable supply of necessary pharmaceuticals and will continue to work with the Federation of Pharmaceutical Manufacturers' Associations of Japan and pharmaceutical wholesalers to ensure prompt delivery to people in the affected areas.
Regarding domestic policies related to the pharmaceutical industry, various comprehensive measures have been taken to ensure a prompt and stable supply of pharmaceuticals. In addition, at the end of 2023, the "Conceptual Council for Prompt Delivery of the Latest Drugs to the Public through Enhanced Drug Discovery" will be established, and we look forward to the measures that will be put forth by this council. From the perspective of the medical care system, we are looking forward to the triple revision of medical, nursing care, and welfare services for the disabled in FY2024, which will reaffirm the importance of innovation in the drug pricing system, including the evaluation of innovative new drugs and the introduction of selective care for long-listed drugs, and we positively accept the results of these efforts. Amidst this recognition of the environment, the pharmaceutical industry is now at a turning point, which means that we must proceed with the implementation phase toward our goal.
Japan Pharmaceutical Manufacturers Association
Chairman Hiroaki Ueno
At this turning point, I would like to contribute to the extension of healthy life expectancy of the Japanese people and the development of the Japanese economy by realizing a virtuous cycle of "strengthening Japan's drug discovery capabilities," which is the main mission of the pharmaceutical industry, and "appropriate evaluation of innovation" through environmental improvement. I have been working with this in mind since assuming the position of Chairman. While each of these initiatives is of course important, it is of the utmost importance that they be integrated into a virtuous cycle. As a result, we will be able to strengthen Japan's drug discovery capabilities and eliminate drug lag/drug loss, which will lead to the delivery of innovative new drugs to patients.
We believe that this virtuous cycle will lead to an increase in people's healthy life expectancy, improved wellbeing, higher labor productivity, and economic growth, and that the profits generated will lead to investment in further innovation, in other words, a virtuous cycle for society as a whole. With this in mind, we will continue to drive the activities of the Pharmaceutical Manufacturers Association of Japan. We look forward to your continued support and encouragement.
(From the press conference held on February 15 by the head of the Pharmaceutical Manufacturers Association of Japan)
Japan Pharmaceutical Manufacturers Association (JPMA)
Japan Pharmaceutical Manufacturers Association (JPMA)
Founded in 1968, the Pharmaceutical Manufacturers Association of Japan (PMAJ) is a voluntary association of R&D-oriented pharmaceutical companies that has contributed to global healthcare through the development of innovative new ethical drugs under the motto "Realization of Patient Participatory Medicine".
The Pharmaceutical Manufacturers Association of Japan (PMAJ) is engaged in a multifaceted program of activities to solve various problems common to the pharmaceutical industry, to deepen understanding of pharmaceuticals, and to promote international collaboration. In addition, we are committed to the sound development of the pharmaceutical industry, particularly by strengthening our policy formulation and advocacy activities, addressing internationalization, and reinforcing our public relations system.
Aiming to contribute to society through the development of new drugs Japan Pharmaceutical Manufacturers Association